BFG
TCRT icon

Bleakley Financial Group’s Alaunos Therapeutics TCRT Stock Holding History

Bleakley Financial Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-95
Closed -$1.01K – 1027
2023
Q4 		$1.01K Hold
95
– – ﹤0.01% 950
2023
Q3 		$1.88K Sell
95
-2
-2% -$86 ﹤0.01% 884
2023
Q2 		$7.41K Buy
97
+6
+7% +$485 ﹤0.01% 926
2023
Q1 		$8.56K Sell
91
-7
-7% -$666 ﹤0.01% 905
2022
Q4 		$9.59K Buy
+98
New +$14.2K ﹤0.01% 869

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Bleakley Financial Group's TCRT Position: Q1 2024 in Review

Bleakley Financial Group sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 95 shares — an estimated $1.01K sold.

Bleakley Financial Group first reported a position in TCRT in Q4 2022 and held it in 5 quarters. The position peaked at $9.59K in Q4 2022. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Bleakley Financial Group reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 95 Alaunos Therapeutics shares in Q1 2024, an estimated $1.01K.
  • Bleakley Financial Group first reported a position in Alaunos Therapeutics in Q4 2022 and held it in 5 quarters.
  • Bleakley Financial Group's Alaunos Therapeutics position peaked at $9.59K in Q4 2022.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Bleakley Financial Group's 13F filing for Q1 2024, filed 8 May 2024.